159 results about "Antigenic Specificity" patented technology

T cell immune responses are enhanced by presentation of antigen to CD8⁺ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By inhibiting apoptosis in the vicinity of a T cell responses to such a nucleic acid immunogen, even more potent immune responses are attained. The present strategy prolongs the survival of DNA-transduced cells, including dendritic cells (DCs), thereby enhancing the priming of antigen-specific T cells and increase potency. Co-delivery of DNA encoding an inhibitor of apoptosis, including (a) BCL-xL, (b) BCL-2, (c) XIAP, (d) dominant negative caspase-9, or (e) dominant negative caspase-8, or (f) serine protease inhibitor 6 (SPI-6) which inhibits granzyme B, with DNA encoding an antigen, prolongs the survival of transduced DCs and results in significant enhancement of antigenspecific T cell immune responses that provide potent antitumor effects. Thus, co-administration of a DNA vaccine encoding antigen linked to an IPP along with one or more DNA constructs encoding an anti-apoptotic protein provides a novel way to enhance vaccine potency.

A bridging assay that utilizes a multivalent MHC binding molecule to enumerate the number of antigen-specific CTLs in a particular sample and also determines the functional capability of the CTL population in the sample is provided. In one embodiment, the assay is used to measure the effector function of any tetramer-positive CTL using a single non-MHC-containing target cell line that is adapted to form an antibody bridge with the tetramer. Furthermore, effector function and enumeration can be measured by flow cytometry, and additional markers residing on either effector or target cell populations may be detected using antibodies coupled with other fluorochromes. The tetramer bridging assay will allow investigators to easily determine the lytic capacity and antigenic specificity of CTLs using a commercially available reagent in a non-radioactive assay.

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

Autoantibodies in biological samples such as serum can result from changes to biomolecules (e.g., proteins, polysaccharides, and lipids) that are associated with disease. Such autoantibodies are useful biomarkers because they frequently appear early in disease and are readily accessible, particularly in biological fluids such as blood and serum. CT antigens are particularly useful for detecting autoantibodies correlated with cancer. Numerous population-based profiles for pluralities of different autoantibody species, at least some of which are specifically reactive with CT antigens, allow for simultaneous assessment of multiple disease-associated analytes is a single test, which can be more effective in diagnostics and drug development than individual profiles. The instant invention provides autoantibody detection array devices that include a plurality of independently selected autoantibody-reactive reagent species, such as full-length CT antigens or the antigenic portions thereof, disposed on a substrate. Such arrays can be used to screen biological samples taken from patients or other subjects for diagnostic, drug development, and other applications.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E7_11-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.

The invention provides a preparation method and application of a new therapeutic vaccine for dendritic tumor cells. The therapeutic tumor vaccine is chemotherapeutic drug induced tumor antigen, wherein, the dendritic cells are loaded and activated. The chemotherapeutic medicament induced tumor antigen contains a plurality of immunostimulation molecules as well as tumor-associated and specific antigen, which can remarkably carry out chemotaxis and activation on immunocytes such as the dendritic cells, T-cells (thymus-dependent lymphocytes) and the like, stimulate the dendritic cells to be mature and express a plurality of cell factors and chemotactic factors, effectively induce immune response reaction with antigenic specificity and non-specificity and strengthen body immune function. The therapeutic vaccine provided by the invention can be used for preventing and treating tumors and has the characteristics of simple preparation process, low cost, strong specificity, obvious curative effect and the like.

The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

The invention relates to a genetic engineering antibody, in particular to a vascular Endothelial Growth Factor (VEGF) acceptor 2/CD3 bispecific single-chain antibody. The bispecific single-chain antibody comprises two binding sites respectively having antigenic specificity on the VEGF acceptor 2 and CD3. The invention further relates to nucleotide sequence coding the bispecific antibody, a carrier containing nucleotide sequence, and a host cell transfected by the carrier. The VEGF2/CD3 bispecific single-chain antibody has small molecular weight and immunogenicity, is easy to penetrate throughcompact tumor barrier and enters the microcirculation around solid tumor, thus having application prospects in preparing tumor treatment drugs.

Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.

Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.

The invention provides a preparation method and an application of a nanogold composite material immunosensor. The method comprises the following steps: dispersing aminated Fe3O4 nano magnetic beads into a Tris buffer solution and connecting with a cancer biomarker antibody (Ab1) as an easy-to-separate immunoprobe; dispersing a hollow polydopamine-nanogold material (PDA-Au) into the Tris buffer solution and connecting with a cancer biomarker antibody (Ab2) as an immune recognition material. Ab1 and Ab2 are specifically combined with a corresponding cancer marker antigen to form a sandwich immune system. The immune system is separated out through the magnetic property, then is added to a mixed water solution of p-nitrophenol and sodium borohydride, and is determined through an ultraviolet visible instrument. The linear range of immune detection of the nanogold composite material immunosensor prepared by the method is 0-100U/mL; the detection lower limit reaches 0.05U/mL; and the related coefficient reaches 0.998.